Identifying and Solving Top Challenges to Oncology Biomarker Testing

Video Library —December 18, 2018
David L Rimm, MD, PhD
Professor of Pathology and Medicine (Oncology)
Yale University School of Medicine
New Haven, CT
Roy S. Herbst, MD, PhD
Ensign Professor of Medicine
Chief of Medical Oncology
Director, Thoracic Oncology Research Program Associate Director for Translational
Research Yale Comprehensive Cancer Center
Yale School of Medicine
New Haven, CT
Drs. David Rimm and Roy Herbst identify the top challenges in the area of biomarker testing as well as solutions to these challenges, including availability of sufficient tissue for a large number of biomarker assays, the time some biomarker tests require for completion, the need for a tight association of test results with clinical outcomes, and the development of companion diagnostics for certain immunotherapies.
Related Articles
Dealing with Multidrug Combination Therapy for Multiple Myeloma
Charise Gleason, MSN, NP-BC, AOCNP, Chelsea Sprouse, RN-BSN, MSN, NP-C, Kathryn Maples, PharmD, BCOP
|
Video Library
Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, describe their approach to advising patients on combination therapy, especially with multidrug regimens, and counseling them on treatments that may be needed to prevent or treat therapy-related adverse events.
Best Practices in Counseling Multiple Myeloma Patients on Therapeutic Options
Charise Gleason, MSN, NP-BC, AOCNP, Chelsea Sprouse, RN-BSN, MSN, NP-C, Kathryn Maples, PharmD, BCOP
|
Video Library
Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, provide their perspectives on how to counsel patients on the best frontline treatment options for newly-diagnosed MM, and how this differs from relapsed/refractory MM, where individualizing treatment plans based on the patient needs and tolerability of treatment is key.
Landscape Shifts in Treating Multiple Myeloma
Charise Gleason, MSN, NP-BC, AOCNP, Kathryn Maples, PharmD, BCOP, Chelsea Sprouse, RN-BSN, MSN, NP-C
|
Video Library
Charise Gleason, MSN, NP-C, AOCNP, Kathryn Maples, PharmD, BCOP, and Chelsea Sprouse, FNP-C, enumerate the major landscape shifts over the past 5 years in treating MM, including an increasing number of treatment options, the emergence of MRD testing to guide therapy, the availability of clinical trials, and the deeper, more durable responses new agents provide.
Last modified: January 17, 2019

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code